PDCD1 and melanoma: The combination of DGBA-OVA-CpG nanovaccine with anti-PD-1 blockade significantly reduced the growth of melanoma in mice compared to that in the control group (by more than 50%), and the survival rate increased by nearly 37.5% (100).